Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 593-596

  Enokimura, Naoyuki ^a   Shiraki, Katsuya ^a   Kawakita, Tomoyuki ^a   Saitou, Yukiko ^a   Inoue, Hidekazu ^a   Okano, Hiroshi ^a   Yamamoto, Norihiko ^a   Deguchi, Masatoshi ^a   Sakai, Takahisa ^a   Ohmori, Shigeru ^a   Fujikawa, Katsuhiko ^a   Murata, Kazumoto ^a   Niki, Yasuo ^a   Nakano, Takeshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Hepatocellular carcinoma; Interferon therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 0037231126     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 211: 277-287, 1990.
2. Tong MJ, el-Farra NS, Reikes AR and Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332: 1463-1466, 1995.
3. Yano M, Kumada H, Kage M, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J and Okuda K.: The long-term pathological evolution of chronic hepatitis C. Hepatology 23: 1334-1340, 1996.
4. Poynard T, Bedossa P and Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825- 832, 1997.
5. Fattovich G, Giustina G, Deggos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW and Realdi G: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 63-72, 1997.
6. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo Q-L, Houghton M and Kuo G: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6547-6549, 1990.
7. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donata MF, Piva A, Di Carlo V and Dioguardi N: Hepatocallular carcinoma in Italian patients with cirrhosis. N Engl J Med 325: 675-680, 1991.
8. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H et al.: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328: 1797-1801, 1993.
9. Takano S, Yokosuka O, Imazeki F, Tagawa M and Omata M: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21: 650-655, 1995.
10. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL et al.: Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321: 1501-1506, 1989.
11. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM and Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989.
12. Hagiwara H, Hayashi N, Mita E, Ueda K, Takahara T, Kasahara A, Fusamoto H and Kamada T.: Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 15: 37-41, 1992.
13. Hagiwara H, Hayashi N, Mita E, Takahara T, Kasahara A, Fusamoto H and Kamada T: Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104: 877-883, 1993.
14. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y et al.: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21: 291-297, 1995.
15. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takahara T, Haruna Y, Naito M, Fusamoto H and Kamada T: Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22: 135-142, 1995.
16. Fried MW and Hoofnagle JH: Therapy of chronic hepatitis C. Semin Liver Dis 15: 82-91, 1995.
17. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshida K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K and The Osaka Liver Disease Study Group: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27: 1394-1402, 1998.
18. Tamori A, Kuroki T, Nishiguchi S, Morimoto H, Morimoto M, Hirrohashi K, Kinoshita AH and Kobayashi K: Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology 43: 1079-1083, 1996.
19. Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kumada K, Sakakibara K, Kano H and Lau JY: Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol 11: 955-958, 1996.
20. Tong MJ, Lai LP and Murakami-Mori K: Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy. West J Med 167: 103-105, 1997.
21. Yamaguchi K, Omagari K, Kinoshita H, Yoshioka S, Furusu H, Takeshima F, Nakashima A, Yamaguchi H and Kohno S: Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. J Clin Gastroenterol 29: 207-209, 1999.
22. Miyano S, Togashi H, Shinzawa H, Sugahara K, Matsuo T, Takeda Y, Saito K, Saito T, Ishiyama S, Kaneko M and Takahashi T: Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol 14: 928-930, 1999.
23. Yamada M, Ichikawa M, Matsubara A, Ishiguro Y and Yokoi S: Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C virus with interferon therapy. Eur J Gastroenterol Hepatol 12: 1029-1032, 2000.
24. Enokimura N, Ogasawara M, Dohi K, Endou T, Mori T, Matsuzaki O, Fujimoto M, Matsuda Y, Takase K and Nakano T: A case of chronic hepatitis C who developed hepatocellular carcinoma after sustained response to interferon therapy. Jpn J Intern Med 86: 139-141, 1997.
25. Okanoue T, Yasui K, Sakamoto S, Minami M, Nagao Y, Itoh Y, Kagawa K and Kashima K: Circulating HCV RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 16: 241-247, 1996.
26. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima Kei and The Viral Hepatitis Therapy Study Group: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 30: 653-659, 1999.
27. Ikeda K, Saitoh S, Koida I, Arase Y, Tsuboya A, Chayama K, Kumada H and Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18: 47-53, 1993.
28. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y and Kobayashi K: Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12: 680-687, 1990.
29. Okanoue T, Itoh Y, Kirishima T, Daimon Y, Toyama T, Morita A, Nakajima T, Minami M and The Viral Hepatitis Study Group: Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatology research 23: 62-77, 2002.
30. Yoshida H, Shiratiri Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G and Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131: 174-181, 2002.
31. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H and Omata M: Histologic improvement of fibrosis in patients with chronic hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132: 517-524, 2000.
32. Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, Hayakawa T and Fukuda Y: Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 16: 1131-1137, 2001.